Medical news
-
Novo Nordisk announces FDA approves the Biologics License Application for ESPEROCT®
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
-
WFH publication explores challenges and opportunities of gene therapy
In the first of a series of round table meetings, the World Federation of Hemophilia (WFH) Gene Therapy Round Table was convened in April 2018...
-
WFH supports MASAC’s recommendation on the risks of gene therapy trials for hemophilia
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
-
Now available: report on the Annual Global Survey 2017
The Report on the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) 2017 is now available in print and online at www.wfh.org/globalsurvey. The report includes...
-
New gene therapy CME activity: Updates on Clinical Trials of Gene Therapy in Hemophilia
The World Federation of Hemophilia (WFH) is pleased to announce the launch of the fifth and final activity in Clinical Advances in Gene Therapy for...
-
WBDR reaches important milestones
The World Bleeding Disorders Registry (WBDR) provides a global platform for hemophilia treatment centres (HTCs) to collect standardized data on people with hemophilia. The WFH...
-
New gene therapy CME activity: The Science of Gene Therapy for Hemophilia
The World Federation of Hemophilia (WFH) is proud to announce the launch of the next activity in Clinical Advances in Gene Therapy for Hemophilia, an...
-
WFH WBDR Research Support Program announced
The World Federation of Hemophilia (WFH) is pleased to announce the launch of the WFH World Bleeding Disorders Registry (WBDR) Research Support Program. The WBDR...
-
New gene therapy CME program launched
The World Federation of Hemophilia (WFH) is proud to announce the launch of Clinical Advances in Gene Therapy for Hemophilia, an online continuing medical education...
